



Enstilar[®] (calcipotriene/betamethasone dipropionate) – Expanded indication

- On July 31, 2019, [Leo Pharma](#) announced the [FDA approval](#) of [Enstilar \(calcipotriene/betamethasone dipropionate\)](#) topical foam, for the topical treatment of plaque psoriasis in patients 12 years of age and older.
 - Previously, Enstilar was approved for the topical treatment of plaque psoriasis in patients 18 years and older.
- The safety and effectiveness of Enstilar for the treatment of mild to severe plaque psoriasis have been established in pediatric patients age 12 to 17 years.
 - The use of Enstilar for this indication is supported by evidence from adequate and well-controlled trials in adults and from one uncontrolled trial in 106 adolescents age 12 to 17 years with psoriasis of the body and scalp.
- The recommended dosage regimen for patients 12 years of age and older is to apply Enstilar to affected areas once daily for up to 4 weeks. Discontinue Enstilar when control is achieved.
 - Patients should not use more than 60 grams every 4 days.
 - Refer to the Enstilar dosing label for additional administration recommendations.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.